文献速递肝病消化道肿瘤与早癌

血管紧张素转换酶抑制剂可预防非酒精性脂肪性肝病患者的肝脏相关事件

Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.
PubMed 文献 · Hepatology · 2022-01-24

这项回顾性全地区队列研究纳入2000年1月至2014年12月诊断的12327例成人非酒精性脂肪性肝病患者,评估ACEI/ARB对肝癌和肝硬化并发症风险的影响。经倾向评分加权后,ACEI治疗与肝脏相关事件、肝癌及肝硬化并发症风险降低相关,而ARB无此关联;亚组分析中ACEI在慢性肾脏病患者中肝脏相关事件减少幅度更大。

要点

  • ACEI治疗与NAFLD患者肝脏相关事件风险降低相关(加权SHR 0.48,95%CI 0.35-0.66,p<0.001)。
  • ACEI与肝癌风险降低(加权SHR 0.46)及肝硬化并发症风险降低(加权SHR 0.42)相关,ARB无此关联。
  • 亚组分析中ACEI在慢性肾脏病患者中肝脏相关事件减少幅度更大(CKD加权SHR 0.74 vs 非CKD加权SHR 0.15)。

核心结论

  • ACEI而非ARB治疗与NAFLD患者肝脏相关事件风险降低相关,尤其在慢性肾脏病患者中。

研究设计与样本

  • 回顾性全地区队列研究,纳入2000年1月至2014年12月诊断的成人NAFLD患者,随访至少5年。
  • 共分析12327例NAFLD患者(平均年龄54.2±14.7岁;6163例男性[50.0%]),其中6805例接受ACEI、2877例接受ARB。
  • ACEI或ARB使用者定义为接受ACEI或ARB治疗至少6个月的患者。
  • 主要终点为肝脏相关事件,定义为肝癌和肝硬化并发症的复合终点。

主要发现

  • 经倾向评分加权后,ACEI治疗与肝脏相关事件风险降低相关(加权SHR 0.48;95%CI 0.35-0.66;p<0.001)。
  • ACEI治疗与肝癌风险降低相关(加权SHR 0.46;95%CI 0.28-0.75;p=0.002)。
  • ACEI治疗与肝硬化并发症风险降低相关(加权SHR 0.42;95%CI 0.27-0.66;p<0.001),ARB无此关联。
  • 亚组分析中,ACEI在慢性肾脏病患者中肝脏相关事件减少幅度大于无慢性肾脏病患者(CKD加权SHR 0.74;95%CI 0.52-0.96;p=0.036;非CKD加权SHR 0.15;95%CI 0.07-0.33;p<0.001)。

关键数值与推荐

  • ACEI使用者定义为接受ACEI治疗至少6个月。
  • ARB使用者定义为接受ARB治疗至少6个月。
  • 主要终点肝脏相关事件为肝癌和肝硬化并发症的复合终点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) can inhibit liver fibrogenesis in animal models. We aimed to evaluate the impact of ACEI/ARB use on the risk of liver cancer and cirrhosis complications in patients with NAFLD. APPROACH AND RESULTS: We conducted a retrospective, territory-wide cohort study of adult patients with NAFLD diagnosed between January 2000 and December 2014 to allow for at least 5 years of follow-up. ACEI or ARB users were defined as patients who had received ACEI or ARB treatment for at least 6 months. The primary endpoint was liver-related events (LREs), defined as a composite endpoint of liver cancer and cirrhosis complications. We analyzed data from 12,327 NAFLD patients (mean age, 54.2 ± 14.7 years; 6163 men [50.0%]); 6805 received ACEIs, and 2877 received ARBs. After propensity score weighting, ACEI treatment was associated with a lower risk of LREs (weighted subdistribution hazard ratio [SHR], 0.48; 95% CI, 0.35-0.66; p < 0.001), liver cancer (weighted SHR, 0.46; 95% CI, 0.28-0.75; p = 0.002), and cirrhosis complications (weighted SHR, 0.42; 95% CI, 0.27-0.66; p < 0.001), but ARB was not. In subgroup analysis, ACEI treatment was associated with greater reduction in LREs in patients with chronic kidney diseases (CKDs) than those without (CKD-weighted SHR, 0.74; 95% CI, 0.52-0.96; p = 0.036; non-CKD-weighted SHR, 0.15; 95% CI, 0.07-0.33; p < 0.001). CONCLUSIONS: ACEI, rather than ARB, treatment is associated with a lower risk of LREs in NAFLD patients, especially among those with CKD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Zhang X, Wong GL, Yip TC, et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022. PMID: 34939204. doi:10.1002/hep.32294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。